LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance ...
FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.
NDTV Profit on MSN
First-at-home Alzheimer's treatment: US FDA approves Eisai-Biogen's weekly self-injection
The injection is expected to be available by late August 2026 in the US.
The most common side effects of IV lecanemab are headache, infusion-related reactions, and amyloid-related imaging abnormalities, a side effect known to occur with the class of an ...
The FDA has approved a subcutaneous version of isatuximab (Sarclisa Escena, Sanofi-Aventis) for several multiple myeloma (MM) ...
This newer mode of administration for immunotherapy comes with benefits and risks. It is important for a person to work with a doctor when making treatment decisions for upper gastrointestinal (GI) ...
Outcomes following subcutaneous and intravenous treatment with lecanemab for Alzheimer’s disease were comparable, according ...
Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena ...
RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102No adverse events attributed to ...
A person receives subcutaneous immunotherapy as an injection under the skin. This treatment method has shown similar effectiveness to intravenous (IV) infusions that healthcare professionals often use ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a ...
Eisai and Biogen have announced that the U.S. Food and Drug Administration has approved a supplemental biologics licence application for a once weekly subcutaneous initiation dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results